The Crohn’s disease(CD) therapy market will continue to evolve over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) helped transform the treatment landscape, especially for patients with moderate to severe disease, despite these agent’s limitations in efficacy (e.g., patients lose response over time) and safety risks. Takeda’s Entyvio, a cell adhesion molecule (CAM) inhibitor, and the introduction of the first-in-class interleukin (IL)-12/23 inhibitor, Janssen’s Stelara, have expanded physicians’ treatment armamentarium, especially for patients refractory to TNF-α inhibitors. Emerging therapies, which offer more-convenient formulations and/or havenovel mechanisms of action (e.g., Galapagos/Gilead’s filgotinib, TiGenix/Takeda’s Alofisel, AbbVie’s risankizumab), together with the increasing availability of biosimilar agents, will only intensify the competition.
QUESTIONS ANSWERED
What are key opinion leaders’ (KOLs’) insights on current treatment options (e.g., Remicade, Humira)? What is their perception of biosimilar agents? What factors drive their treatment decisions?
How have/will the newer, non-TNF biologics (e.g., Janssen’s Stelara, Takeda’s Entyvio, Roche’s etrolizumab) affect the CD treatment algorithm?
What do KOLs think about emerging oral therapies (e.g., Galapagos/Gilead’s filgotinib, AbbVie’s upadacitinib)? What impact will stem-cell therapy (i.e., TiGenix/Takeda’s Alofisel) have on the CD market?
How will the market evolve over the next ten years? What are KOLs’ insights on current treatment options for CD (e.g., Remicade, Humira, Inflectra/Remsima)? What factors drive their treatment decisions?
PRODUCT DESCRIPTION
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.